Cosmo Pharmaceuticals N.V.

COPN.SW

Medical - Pharmaceuticals · Healthcare

Price

CHF 58.70

+0.00 (+0.00%)

Market Cap

CHF 1.01B

Exchange

SIX Swiss Exchange

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Dividends

Mixed

Track this stock — start free trial

Share count falling — buybacks

−5.5% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 16.9M (2021) → 16.0M (2025)

Winston Score History

The full picture

Cosmo Pharmaceuticals is a specialty drug company based in Ireland and Italy that focuses on diseases of the gut, particularly the colon and intestines. Its main products include Methylene Blue MMX, a dye used during colonoscopies to help doctors spot abnormal tissue, and a range of treatments for conditions like ulcerative colitis and bowel infections. The company sells primarily to hospitals, gastroenterologists, and healthcare systems in Europe and North America.

Cosmo makes money by selling its drugs directly and by licensing its proprietary drug-delivery technology, called MMX, to other pharmaceutical companies in exchange for royalties and milestone payments. It operates mainly across Europe and the United States, and its patented MMX technology platform gives it some protection against direct competition. However, the company is currently operating at a loss, and its growth depends heavily on expanding adoption of its colonoscopy products and successfully advancing its pipeline of gut-focused drugs through regulatory approval.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-3.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-115.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

€32M/ year

↑ Rising (+8559% vs prior year)

30.8% of revenue

1.7x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

49.8%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~6 years

€217M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

€217M cash & investments at current burn rate

Heavy R&D investment

Cosmo Pharmaceuticals N.V. is putting 31% of revenue into R&D and that number is rising. That's 1.7x the sector average. With 6+ years of cash runway, they have time to let it pay off.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

44.5%

Healthy — 44.5% gross margin

Profit after running costs

Operating Margin

-18.8%

Losing money on operations — -18.8%

Return on the money invested

ROCE

-2.4%

Weak — -2.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-43.7%

Shrinking sales (-43.7% YoY)

Profit growth

EPS YoY

-111.5%

Earnings shrinking (-111.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-23.2%

Burning cash (-23.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

3.33%

Moderate income — 3.33% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial